EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)ÄquivalenzstudieMultizentrische StudieOpen Access · CC BY 4.0

Outcomes by Faricimab Treatment Interval at Week 48 of TENAYA-LUCERNE Phase III Trials in Neovascular Age-Related Macular Degeneration

Nikolas J S London, Chui Ming Gemmy Cheung, Stephan Michels, Aachal Kotecha, Philippe Margaron, Audrey Souverain, Jeffrey R Willis, Timothy Y Y Lai

Ophthalmology Retina · 2025

DOI: 10.1016/j.oret.2025.05.004 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Ophthalmology Retina, 2025. Verfasst von Nikolas J S London und 7 weiteren Autor:innen. Beteiligte Einrichtung: Retina Consultants San Diego, San Diego, California. Electronic address: london@rcsd.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Macula Lutea, Visual Acuity, Wet Macular Degeneration. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche, F. Hoffmann-La Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedMacula LuteaVisual AcuityWet Macular DegenerationAgedFemaleHumansMaleMiddle AgedAngiogenesis InhibitorsAngiopoietin-2Dose-Response Relationship, DrugDouble-Blind MethodFluorescein AngiographyFollow-Up StudiesFundus OculiIntravitreal InjectionsTime FactorsTomography, Optical CoherenceTreatment OutcomeVascular Endothelial Growth Factor AAntibodies, Bispecific

Stichwörter der Autor:innen

Angiopoietin-2 (Ang-2)DurabilityFaricimabNeovascular age-related macular degenerationVEGF-A

Substanzen

Angiogenesis InhibitorsAngiopoietin-2Antibodies, Monoclonal, HumanizedfaricimabVascular Endothelial Growth Factor AAntibodies, Bispecific

Autor:innen und Institutionen

  • Retina Consultants San Diego, San Diego, California. Electronic address: london@rcsd.com.
  • Singapore National Eye Centre, Duke-NUS Medical School, National University of Singapore, Singapore.
  • Eye Clinic Zurich West, Zurich, Switzerland; University of Zurich, Zurich, Switzerland.
  • Roche Products Ltd., Welwyn Garden City, UK.
  • F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Genentech, Inc., South San Francisco, California.

Förderung

  • Roche
  • F. Hoffmann-La Roche

Zitieren

APA

London, N. J. S., Cheung, C. M. G., Michels, S., Kotecha, A., Margaron, P., Souverain, A., Willis, J. R., & Lai, T. Y. Y. (2025). Outcomes by Faricimab Treatment Interval at Week 48 of TENAYA-LUCERNE Phase III Trials in Neovascular Age-Related Macular Degeneration. Ophthalmology Retina. https://doi.org/10.1016/j.oret.2025.05.004

Vancouver

London NJS, Cheung CMG, Michels S, Kotecha A, Margaron P, Souverain A, et al. Outcomes by Faricimab Treatment Interval at Week 48 of TENAYA-LUCERNE Phase III Trials in Neovascular Age-Related Macular Degeneration. Ophthalmology Retina. 2025. doi:10.1016/j.oret.2025.05.004

BibTeX
@article{London2025,
  author = {London, Nikolas J S and Cheung, Chui Ming Gemmy and Michels, Stephan and Kotecha, Aachal and Margaron, Philippe and Souverain, Audrey and Willis, Jeffrey R and Lai, Timothy Y Y},
  title = {Outcomes by Faricimab Treatment Interval at Week 48 of TENAYA-LUCERNE Phase III Trials in Neovascular Age-Related Macular Degeneration},
  journal = {Ophthalmology Retina},
  year = {2025},
  doi = {10.1016/j.oret.2025.05.004}
}
Kostenlos starten →